---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-007879"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2025-12-11T23:59:59+00:00"
generated_at: "2026-05-16T13:29:26.892985+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arbutus updates LNP litigation; Moderna trial March 2026, Pfizer/BioNTech awaits scheduling

## Summary
- Global COVID-19 vaccine sales since launch total ~$145BN between Moderna and Pfizer/BioNTech.
- US Moderna jury trial set for March 9, 2026 in Delaware; summary judgment/Daubert rulings expected before trial.
- Ex-US Moderna litigation initial hearings expected in 2026 in UPC, Japan, Switzerland, Canada.
- Pfizer/BioNTech litigation: Markman ruling in Sep 2025 viewed favorably; awaiting trial scheduling.

## SEC filing metadata
- accession: 0001171843-25-007879
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2025-12-11T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184325007879/0001171843-25-007879-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184325007879/f8k_121025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-007879
- JSON: https://secwatch.observer/filing/0001171843-25-007879.json
- Plain text: https://secwatch.observer/filing/0001171843-25-007879.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.